RABEPRAZOLE 20MG DOMPERIDONE 30MG SR PELLETS CAPSULES is a multiparticulate oral formulation combining rabeprazole 20 mg with domperidone 30 mg in a capsule containing specially designed pellets. Unlike a conventional compressed tablet, this dosage form relies on the preparation, coating, size distribution, and controlled filling of individual pellets. The formulation therefore requires careful coordination between pellet manufacturing, protective coating technology, sustained-release design, capsule filling, and stability control. For pharmaceutical companies developing a diversified PCD Pharma Franchise portfolio, such multiparticulate formulations offer a technically structured product-development approach.
The defining feature of this product is its pellet-based architecture. Pellets are small, relatively uniform multiparticulate units that can be engineered with different functional layers depending on the formulation requirements. In a combination product containing rabeprazole and domperidone, the two active ingredients may require different processing and coating approaches before being incorporated into the final capsule.
Rabeprazole-containing pellets can be developed with a protective layer designed to help maintain the required formulation environment. Domperidone pellets can be processed separately with a release-controlling coating system appropriate for the sustained-release design.
This approach allows the formulation team to work on the characteristics of each active component before bringing the pellet populations together during capsule filling.
Pellet development begins with selecting an appropriate starter material or pelletization platform and establishing the required drug-loading process. Depending on the manufacturing technology, active ingredients may be layered onto starter cores or incorporated through a suitable pelletization process.
The size distribution of the pellets is important because significant variation in pellet dimensions can influence coating uniformity, flow characteristics, capsule fill consistency, and release behaviour. Screening or classification may therefore be used to remove excessively large or small particles.
During processing, parameters such as binder concentration, spray rate, inlet conditions, product temperature, and pelletization speed can affect pellet growth and surface characteristics. The resulting pellets are evaluated for shape, size distribution, mechanical integrity, and flow before progressing to functional coating.
Coating technology is a major part of the development of RABEPRAZOLE 20MG DOMPERIDONE 30MG SR PELLETS CAPSULES. Rabeprazole pellets may require a protective coating architecture, while domperidone pellets require a controlled-release layer designed to regulate the release characteristics of the active ingredient.
Coating materials are applied under controlled process conditions to achieve a consistent film around individual pellets. Spray rate, atomization, inlet air temperature, product-bed temperature, coating weight gain, and drying conditions can influence the final coating structure.
The coated pellets are subsequently evaluated for coating integrity and release behaviour. Dissolution testing at defined intervals can help characterize the performance of the sustained-release pellet system. The coating process must be reproducible because small changes in film thickness or uniformity can affect the release profile.
After pellet preparation and coating, the different pellet populations are blended or otherwise combined according to the approved formulation design. The resulting multi particulate mixture must maintain suitable flow so that each capsule receives the specified quantity.
Capsule-filling equipment is adjusted according to pellet density, flow properties, capsule size, and target fill weight. In-process checks can include capsule weight variation, fill consistency, appearance, locking integrity, and leakage or powder/pellet loss during handling.
Environmental control can also be important during capsule production, particularly where the coating system or active ingredients have sensitivity to moisture. Proper material handling and controlled transfer between processing stages help minimize damage to coated pellets.
Quality testing for this formulation extends beyond simple assay measurement because the product contains multiple pellet populations with different functional characteristics. The individual active ingredients can be evaluated using suitable identification and assay procedures, while related substances may be monitored to assess chemical stability.
Physical testing can include capsule weight, pellet size distribution, coating integrity, moisture content, and other applicable parameters. Dissolution testing is especially important for a sustained-release multi particulate formulation because it provides information about the release behaviour of the coated domperidone pellets and the overall dosage form.
Stability studies may monitor assay, degradation products, dissolution profile, capsule integrity, pellet appearance, and moisture-related changes over the proposed shelf life. Analytical methods should be sufficiently specific to evaluate both active components independently.
Packaging for RABEPRAZOLE 20MG DOMPERIDONE 30MG SR PELLETS CAPSULES should provide suitable protection against environmental exposure while maintaining capsule and pellet integrity during transportation and storage. Blister or strip packaging can be selected according to the moisture-protection and presentation requirements established during development.
Packaging studies may assess seal integrity, moisture transmission, compatibility, and stability under defined storage conditions. The capsule shell and coated pellets should remain physically intact without significant changes in appearance or release characteristics.
For pharmaceutical businesses, this multiparticulate formulation can form a specialized component of a PCD Pharma Franchise portfolio. Controlled pellet production, reproducible coating technology, accurate capsule filling, analytical verification, and protective packaging collectively support consistent product development and organized pharmaceutical distribution.
Rabeprazole 20mg + Domperidone 30mg SR Pellets Capsules with details on pellet technology, manufacturing, quality control and packaging.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech